Odeska
Odeska, licence 80087054: active licence in Health Canada data. The French and European references below do not constitute authorisation for sale in France or an assessment of safety or efficacy.
Licensed Natural Health Products Database (LNHPD), Health Canada: licensed products, ingredients, doses, uses and risks, retrieved 27 October 2026.
Contains information licensed under the Open Government Licence – Canada (Health Canada, LNHPD)
Licence du gouvernement ouvert – Canada 2.0 (OGL-Canada 2.0)
Natural health product licensed in Canada
- Licence holder
- Odeska Incorporated
- NPN or DIN-HM
- 80087054
- Status
- Active licence
- Licence date
- 13 July 2018
- Revision date
- Not provided
- Form
- Capsule
- Route of administration
- Orale
- Application type
- Officinale
If this product were sold in France
No point flagged by the rules we apply.
A daily quantity is calculated only for an explicit adult oral dosage, stated per day and in a solid unit matching the product form. Ambiguous units, liquids, powders and paediatric doses are not extrapolated. A quantity not calculated is not compared with dose limits. This analysis does not constitute authorisation for sale in France or an assessment of safety or efficacy.
Composition
| Medicinal ingredient and source | Per dosage unit, according to the source | Maximum per day, adult |
|---|---|---|
| 1,3,7-triméthylxanthine Source : Caféine | 100.0 milligramme | Not calculated |
Non-medicinal ingredients
Stéarate de magnésium, Hypromellose, Cellulose
Recommended doses in Canada
| Population | Age | Quantity per serving | Frequency |
|---|---|---|---|
| Adultes | minimum: 19.0 Année(s) | 1.0 Capsule | minimum: 1.0 Tous les jours ; maximum: 2.0 Tous les jours |
Uses authorised in Canada
Temporarily promotes alertness and wakefulness. temporarily enhances cognitive performance. Helps to relieve fatigue, and symptoms of stress, such as mental fatigue.
A use authorised in Canada is not an authorised health claim in the European Union. See the health claims register.
Warnings in Canada
- Contre-indications
do not take if your doctor advises you against caffeine consumption, if you have hypertension, are pregnant, and if you have a rapid or irregular heart rate. If you have bipolar disorder or bipolar spectrum disorder, do not use this product. If you experience irritability, discontinue use.
- Effets indésirables connus
May cause nervousness irritability, anxiety, headaches, reduction of sleep quality, rapid hear rate, and gastrointestinal disturbances if taken in large quantities.
- Précautions et mises en garde
not a substitute for food, sleep, or a doctor's diagnosis. If symptoms persist or worsen, consult a health care practitioner. If you are pregnant or breastfeeding, consult a health care practitioner prior to use. If you are taking antidepressant medication, taking hormone replacement therapy (HRT) or birth control pills, consult a health care practitioner prior to use. Consult a health care practitioner prior to use if you are taking lithium. Consult a health care practitioner prior to use if you have high blood pressure, glaucoma, and/or detrusor instability (overactive bladder syndrome). Consumption with natural health products (e.g. bitter orange extract, synephrine, octopamine, ephedra) or other drugs (e.g. ephedrine) which increase blood pressure is not recommended. consumption with other caffeine-containing products (e.g. medications, coffee, tea, colas, cocoa, guarana, maté) is not recommended. consult a health care practitioner if you are of childbearing age, pregnant, or breastfeeding. Hypersensitivity/allergy is known to occur, in which case, discontinue use.
Source
Official Health Canada record, licence 80087054
The formula sold in Europe under the same name may differ. This information does not replace advice from a doctor or pharmacist.
The evidence date of this ingredient list is unknown.
Has the product changed? Photograph the packaging.